Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genenta Science SPA GNTA

Healthcare Biotechnology
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including... see more

Recent & Breaking News (NDAQ:GNTA)

Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

GlobeNewswire 13 days ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

GlobeNewswire October 2, 2024

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

GlobeNewswire May 6, 2024

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

GlobeNewswire February 8, 2024

Genenta to Present at Upcoming Scientific and Investor Conferences

GlobeNewswire September 6, 2023

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

GlobeNewswire July 28, 2023

The European Commission Grants Orphan Drug Designation to Temferon(TM) for Treatment of Glioma

GlobeNewswire June 29, 2023

Genenta to Provide Update on Lead Product Temferon(TM)

GlobeNewswire May 16, 2023

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

GlobeNewswire April 26, 2023

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

GlobeNewswire April 3, 2023

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

GlobeNewswire March 2, 2023

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

GlobeNewswire February 7, 2023

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon(TM) Treatment in Glioblastoma Patients

GlobeNewswire November 7, 2022

Genenta Provides First Half 2022 Business Update and Financial Results

GlobeNewswire October 24, 2022

Genenta to Present at Upcoming Scientific and Investor Conferences

GlobeNewswire October 5, 2022

Genenta to Present at Upcoming Investor Conferences

GlobeNewswire September 7, 2022

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

GlobeNewswire July 25, 2022

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

GlobeNewswire May 13, 2022

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

GlobeNewswire May 9, 2022

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

GlobeNewswire May 4, 2022